Inhibitor of 4-Hydroxyphenylpyruvate dioxygenase (HPPD, IC50 = 40 nM1 and 173 nM2) and is in clinical use for the treatment of hereditary tyrosinemia type 13. CD13+ cancer stem cells (CSCs) are dependent on aerobic metabolism of tyrosine - Nitisinone inh
* VAT and and shipping costs not included. Errors and price changes excepted